Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InMed Pharmaceuticals Inc.INM · Entity 8139 | VP Accounting & Controller | December 16, 2022 | December 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InMed Pharmaceuticals Inc.
Report date December 16, 2022 · Filed December 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.78 · Expires 2027-12-15 | Direct | 4,002 |
Reported balance
After 2022-12-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-16 · Grant · Acquired 3,600 · Balance 4,002 F1: The options were granted on 12/16/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on 12/16/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2022 Filed Dec 19, 2022 17:03 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,600 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001213900-22-080994 · ownership.xml · derivative · entry 1 Li Sarah · CIK 0001956288 · VP Accounting & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,002 Underlying: Common shares · 3,600 shares Expires 2027-12-15 F1 · derivative.exercise_date: The options were granted on 12/16/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.